Search for other papers by Sabri Engin Altintop in
Current site
Google Scholar
PubMed
Search for other papers by Tugce Unalan-Altintop in
Current site
Google Scholar
PubMed
Search for other papers by Mustafa Cihangiroglu in
Current site
Google Scholar
PubMed
Search for other papers by Pelin Onarer in
Current site
Google Scholar
PubMed
Search for other papers by Fikriye Milletli-Sezgin in
Current site
Google Scholar
PubMed
Search for other papers by Melih Gozukara in
Current site
Google Scholar
PubMed
Search for other papers by Bilge Gozukara in
Current site
Google Scholar
PubMed
Search for other papers by Erman Zengin in
Current site
Google Scholar
PubMed
Abstract
SARS-CoV-2 virus was initially identified in Wuhan, China, in December 2019 and a global pandemic was declared in March 2020 by World Health Organization. COVID-19 disease is characterized with severe pneumonia and hypoxemia, especially in the elderly population. The elderly population was primarily vaccinated with CoronaVac, which is a whole virion inactivated vaccine (Sinovac Biotech, China) in Turkey. This study aimed to investigate the association of viral load and laboratory parameters with the severity of the disease and vaccination status in elderly (older than 60 years old) COVID-19 patients. The age range of the patients was 61–97 years old with a mean of 71.80. Vaccinated patients had a lower viral load (P = 0.253) in nasopharyngeal swabs during breakthrough COVID-19 infection compared to unvaccinated ones and were hospitalized for a shorter period of time in hospital wards (P = 0.035). A lower number of patients were vaccinated in both moderate (n = 33, 29.20%) and severe/critical group (n = 46, 34.07%) (P = 0.412). Only 17 (32.08%) vaccinated patients were hospitalized in an intensive care unit (ICU), whereas 36 (67.92%) of the ICU patients were unvaccinated (P = 0.931). Severe/critical patients had higher c-reactive protein (CRP), platelet-to-lymphocyte ratio (PLR), fibrinogen, ferritin, and lactate dehydrogenase (LDH) levels compared to the moderate group on the admission day (P < 0.05). Our study suggested that elderly patients vaccinated with CoronaVac had a shorter stay in hospitals and according to our results CRP, PLR, fibrinogen, ferritin, and LDH levels could be used to determine the severity of the infections.
-
1.
European Centre for Disease Prevention and Control. Latest evidence on COVID-19.
-
2.
Organization WH. Background document on the inactivated vaccine Sinovac-CoronaVac against COVID-19: background document to the WHO interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac, 24 May 2021. World Health Organization; 2021.
-
3.
Ministry of health Turkey COVID-19 national guidelines. https://covid19saglikgovtr/TR-66301/covid-19-rehberihtml.2021.
-
4.
Miranda RL, Guterres A, de Azeredo Lima CH, Filho PN, Gadelha MR. Misinterpretation of viral load in COVID-19 clinical outcomes. Virus Res. 2021; 296: 198340.
-
5.
Aykac K, Cura Yayla BC, Ozsurekci Y, Evren K, Oygar PD, Gurlevik SL, et al. The association of viral load and disease severity in children with COVID-19. J Med Virol. 2021; 93: 3077–3083.
-
6.
National Institute of health COVID-19 treatment guidelines. https://wwwcovid19treatmentguidelinesnihgov/overview/clinical-spectrum/2021.
-
7.
COVID-19 vaccine breakthrough infections reported to CDC — United States, January 1–April 30, 2021. MMWR Morb Mortal Wkly Rep 2021; 70: 792–793. http://dx.doi.org/10.15585/mmwr.mm7021e3external.
-
8.
Kang M, Xin H, Yuan J, Ali ST, Liang Z, Zhang J, et al. Transmission dynamics and epidemiological characteristics of SARS-CoV-2 Delta variant infections in Guangdong, China, May to June 2021. Euro Surveill. 2022; 27.
-
9.
Levine-Tiefenbrun M, Yelin I, Katz R, Herzel E, Golan Z, Schreiber L, et al. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat Med. 2021; 27: 790–792.
-
10.
McEllistrem MC, Clancy CJ, Buehrle DJ, Lucas A, Decker BK. Single dose of a mRNA SARS-CoV-2 vaccine is associated with lower nasopharyngeal viral load among nursing home residents with asymptomatic COVID-19. Clinical Infectious Diseases. 2021.
-
11.
Puhach O, Adea K, Hulo N, Sattonnet P, Genecand C, Iten A, et al. Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2. Nat Med. 2022.
-
12.
Harris RJ, Hall JA, Zaidi A, Andrews NJ, Dunbar JK, Dabrera G. Effect of vaccination on household transmission of SARS-CoV-2 in England. N Engl J Med. 2021; 385: 759–760.
-
13.
Recommendation for an emergency use listing of covid-19vaccine (Vero cell), inactivated — submitted by Sinovac. Geneva:World health organization. June 28, 2021. https://extranet.who.int/pqweb/sites/default/files/documents/SINOVAC_TAG_PEG_REPORT_EUL-Final28june2021.pdf.
-
14.
Wilder-Smith A, Mulholland K. Effectiveness of an inactivated SARS-CoV-2 vaccine. N Engl J Med. 2021; 385: 946–948.
-
15.
Cerqueira-Silva T, Katikireddi SV, de Araujo Oliveira V, Flores-Ortiz R, Júnior JB, Paixão ES, et al. Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil. Nat Med. 2022; 28: 838–843.
-
16.
Abarca K, Iturriaga C, Urzúa M, Le Corre N, Pineda A, Fernández C, et al. Kalergis AM, on behalf of the CoronaVac Cl study G. Safety and non-inferiority evaluation of two immunization Schedules with an inactivated SARS-CoV-2 vaccine in Adults: a randomized clinical trial. Vaccines (Basel). 2022; 10.
-
17.
McMenamin ME, Nealon J, Lin Y, Wong JY, Cheung JK, Lau EHY, et al. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study. Lancet Infect Dis. 2022; 22: 1435–1443.
-
18.
Sauré D, O'Ryan M, Torres JP, Zuniga M, Santelices E, Basso LJ. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study. Lancet Infect Dis. 2022; 22: 56–63.
-
19.
Karamese M, Tutuncu EE. The effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on antibody response in participants aged 65 years and older. J Med Virol. 2022; 94: 173–177.
-
20.
Zhang J, He Q, An C, Mao Q, Gao F, Bian L, et al. Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine. Emerg Microbes Infect. 2021; 10: 1598–1608.
-
21.
Guo X, Jie Y, Ye Y, Chen P, Li X, Gao Z, et al. Upper respiratory tract viral ribonucleic acid load at hospital admission is associated with coronavirus disease 2019 disease severity. Open Forum Infect Dis. 2020; 7: ofaa282.
-
22.
Maltezou HC, Raftopoulos V, Vorou R, Papadima K, Mellou K, Spanakis N, et al. Association between upper respiratory tract viral load, comorbidities, disease severity, and outcome of patients with SARS-CoV-2 infection. J Infect Dis. 2021; 223: 1132–1138.
-
23.
Tanner AR, Phan H, Brendish NJ, Borca F, Beard KR, Poole S, et al. SARS-CoV-2 viral load at presentation to hospital is independently associated with the risk of death. J Infect. 2021; 83: 458–466.
-
24.
Pawar RD, Balaji L, Mehta S, Cole A, Liu X, Peradze N, et al. Viral load and disease severity in COVID-19. Intern Emerg Med. 2022; 17: 359–367.
-
25.
Yilmaz A, Marklund E, Andersson M, Nilsson S, Andersson LM, Lindh M, et al. Upper respiratory tract levels of severe acute respiratory syndrome coronavirus 2 RNA and duration of viral RNA Shedding do not differ between patients with mild and severe/critical coronavirus disease 2019. J Infect Dis. 2021; 223: 15–18.
-
26.
Rodriguez C, de Prost N, Fourati S, Lamoureux C, Gricourt G, N'Debi M, et al. Viral genomic, metagenomic and human transcriptomic characterization and prediction of the clinical forms of COVID-19. Plos Pathog. 2021; 17: e1009416.
-
27.
Ng DL, Granados AC, Santos YA, Servellita V, Goldgof GM, Meydan C, et al. A diagnostic host response biosignature for COVID-19 from RNA profiling of nasal swabs and blood. Sci Adv. 2021; 7.
-
28.
Mehta AA, Haridas N, Belgundi P, Jose WM. A systematic review of clinical and laboratory parameters associated with increased severity among COVID-19 patients. Diabetes Metab Syndr. 2021; 15: 535–541.
-
29.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet. 2020; 395: 1054–1062.
-
30.
Sarkar S, Kannan S, Khanna P, Singh AK. Role of platelet-to-lymphocyte count ratio (PLR), as a prognostic indicator in COVID-19: a systematic review and meta-analysis. J Med Virol. 2022; 94: 211–221.
-
31.
Han H, Yang L, Liu R, Liu F, Wu KL, Li J, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med. 2020; 58: 1116–1120.
Editorial Office:
Akadémiai Kiadó Zrt.
Budafoki út 187-187, A/3, H-1117 Budapest, Hungary
Editorial Correspondence:
Acta Microbiologica et Immunologica Hungarica
Institute of Medical Microbiology
Semmelweis University
P.O. Box 370
H-1445 Budapest, Hungary
Phone: + 36 1 459 1500 ext. 56101
Fax: (36 1) 210 2959
E-mail: amih@med.semmelweis-univ.hu
Indexing and Abstracting Services:
- Biological Abstracts
- BIOSIS Previews
- CAB Abstracts
- CABELLS Journalytics
- Chemical Abstracts
- Global Health
- Index Medicus
- Index Veterinarius
- Medline
- Referativnyi Zhurnal
- SCOPUS
- Science Citation Index Expanded
| 2023 | |
|---|---|
| Web of Science | |
| Journal Impact Factor | 1.3 |
| Rank by Impact Factor | Q4 (Immunology) |
| Journal Citation Indicator | 0.31 |
| Scopus | |
| CiteScore | 2.3 |
| CiteScore rank | Q3 (Infectious Diseases) |
| SNIP | 0.389 |
| Scimago | |
| SJR index | 0.308 |
| SJR Q rank | Q3 |
| Acta Microbiologica et Immunologica Hungarica | |
|---|---|
| Publication Model | Hybrid |
| Submission Fee | none |
| Article Processing Charge | 1100 EUR/article (only for OA publications) |
| Regional discounts on country of the funding agency | World Bank Lower-middle-income economies: 50% World Bank Low-income economies: 100% |
| Further Discounts | Editorial Board / Advisory Board members: 50% Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100% |
| Subscription fee 2025 | Online subsscription: 772 EUR / 848 USD Print + online subscription: 860 EUR / 944 USD |
| Subscription Information | Online subscribers are entitled access to all back issues published by Akadémiai Kiadó for each title for the duration of the subscription, as well as Online First content for the subscribed content. |
| Purchase per Title | Individual articles are sold on the displayed price. |
| Acta Microbiologica et Immunologica Hungarica | |
|---|---|
| Language | English |
| Size | A4 |
| Year of Foundation |
1954 |
| Volumes per Year |
1 |
| Issues per Year |
4 |
| Founder | Magyar Tudományos Akadémia |
| Founder's Address |
H-1051 Budapest, Hungary, Széchenyi István tér 9. |
| Publisher | Akadémiai Kiadó |
| Publisher's Address |
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245. |
| Responsible Publisher |
Chief Executive Officer, Akadémiai Kiadó |
| ISSN | 1217-8950 (Print) |
| ISSN | 1588-2640 (Online) |
Monthly Content Usage
| Abstract Views | Full Text Views | PDF Downloads | |
|---|---|---|---|
| Jun 2024 | 0 | 71 | 19 |
| Jul 2024 | 0 | 26 | 8 |
| Aug 2024 | 0 | 38 | 33 |
| Sep 2024 | 0 | 38 | 12 |
| Oct 2024 | 0 | 179 | 13 |
| Nov 2024 | 0 | 69 | 11 |
| Dec 2024 | 0 | 5 | 1 |
Copyright Akadémiai Kiadó AKJournals is the trademark of Akadémiai Kiadó's journal publishing business branch.